2023-506540-16-01RecruitingPhase 2
A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients with Hereditary Angioedema (The ALPHA-SOLAR Trial)
Astria Therapeutics Inc.6 sites in 4 countries26 target enrollmentStarted: November 15, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 26
- Locations
- 6
- Primary Endpoint
- Incidence of adverse events (AEs)
Study Overview
Brief Summary
To assess long-term safety and tolerability of STAR-0215 in participants with Type 1 or Type 2 hereditary angioedema (HAE)
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •At least 18 years of age at the time of Screening.
- •STAR-0215-201 status was 1 of the following: a. Completed all visits through 6 months after their last dose in STAR-0215-201 b. Eligible for participation in STAR-0215-201 (met all inclusion criteria [with the exception of the criterion for the minimum number of HAE attacks during the Run-In Period] and met none of the exclusion criteria) and entered the Run-In-Period, but did not qualify for the Treatment Period because they did not meet the criterion for the minimum number of HAE attacks. c. Eligible for participation in STAR-0215-201 and entered the Run-In Period but did not complete it for reasons other than not meeting the criterion for the minimum number of HAE attacks – eligibility requires consultation with the Medical Monitor; or d. Discontinued participation in STAR-0215-201 (for personal or social reasons) after having completed at least 84 days of trial follow-up since their last dose of STAR-
- •Eligibility requires consultation with the Medical Monitor. Participants who discontinued for safety reasons are not eligible.
- •For participants who are STAR-0215-naïve and were not enrolled in STAR-0215-201: Documented diagnosis of HAE (Type 1 or Type 2). All of the following must be met: a. Documented clinical history consistent with HAE (e.g. subcutaneous [SC] or mucosal, nonpruritic swelling episodes without accompanying urticaria). b. Age at reported onset of first angioedema symptoms 30 years of age or younger, or a family history consistent with HAE Type 1 or Type
- •c. C1-esterase inhibitor protein (C1-INH) antigen or functional level less than 40% of the normal level. Participants with antigen or functional C1-INH level 40% to 50% of the normal level may be eligible if they also have a C4 level below the normal range and a family history consistent with HAE Type 1 or Type
- •Testing for C1-INH and C4 will be performed at Screening. Historical test results for C1-INH may be used to confirm eligibility if the screening C1-INH antigen test or functional level or C4 level laboratory values are inconclusive, after discussion with the Medical Monitor. If the C1-INH functional level by enzyme immunoassay (EIA) does not qualify a participant with known or clinically suspected Type 2 HAE for study eligibility, a chromogenic assay may be obtained after discussion with the Sponsor's Medical Monitor. Functional level via chromogenic assay is inclusionary if the C1-INH functional level is < 74%. In this situation, the chromogenic assay should be ordered by the site per their usual process for ordering the test.
- •For participants who are STAR-0215-naïve and were not enrolled in STAR-0215-201: At least 2 HAE attacks during the Run-In Period, as confirmed by an investigator based on protocol-specified definition of an HAE attack.
Exclusion Criteria
- •Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1 INH (also known as HAE Type 3), idiopathic angioedema, or angioedema associated with urticaria
- •Any exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as hormonal contraceptives or hormone replacement therapy) within 28 days prior to Screening. (Note: These medications are prohibited in STAR-0215-201)
- •Any exposure to androgens (e.g. stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within 7 days prior to Screening. Note: These medications are prohibited in STAR-0215-201
- •Use of therapies prescribed for the prevention of HAE attacks (with the exception of STAR-0215 for participants who received STAR-0215 in STAR-0215-201) prior to Screening: a. lanadelumab within 90 days b. berotralstat within 21 days c. all other prophylactic therapies, discuss with the Medical Monitor Note: These medications are prohibited in STAR-0215-201.
Outcomes
Primary Outcomes
Incidence of adverse events (AEs)
Incidence of adverse events (AEs)
Secondary Outcomes
- Change from baseline in monthly HAE attack rate
- Incidence of monthly HAE attack severity (mild, moderate, and severe)
- Duration of monthly HAE attack (shorter than 12 hours, 12 to 24 hours, 24 to 48 hours, and longer than 48 hours)
- The number of monthly HAE attacks requiring on-demand therapy
- Time to first HAE attack after each dose
- Number of HAE attack-free days
- Proportion of HAE attack-free participants (i.e., participants having 0 HAE attacks during the specified treatment period)
- Concentration of STAR-0215 and the derived PK parameters
- Change in plasma kallikrein activity
- Formation of anti-drug (STAR-0215) antibodies
Investigators
Astria Therapeutics Inc
Scientific
Astria Therapeutics Inc.
Study Sites (6)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerNCT07281976Nanjing Leads Biolabs Co.,Ltd220
Recruiting
Phase 1
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsNSCLCNCT07274813Shanghai Henlius Biotech254
Not yet recruiting
Phase 2
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
Recruiting
Phase 2
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
Recruiting
Phase 3
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease2023-505170-15-00Amicus Therapeutics Inc.34